Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Myriad Genetics, Inc. - Common Stock (NQ: MYGN )

9.700 -0.710 (-6.82%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 13, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 885,990
Open 10.41
Bid (Size) 9.700 (1)
Ask (Size) 10.52 (1)
Prev. Close 10.41
Today's Range 9.690 - 10.47
52wk Range 9.360 - 29.30
Shares Outstanding 91,300,000
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Analyst Sees Bottom For Myriad Genetics Stock, Issues Upgrade
Piper Sandler upgrades Myriad Genetics to Overweight, citing stock stabilization and new leadership. The firm raises its price target to $12.50. 
Via Benzinga
Why Are Myriad Genetics (MYGN) Shares Soaring Today
Shares of genetic testing company Myriad Genetics (NASDAQ:MYGN) jumped 10.6% in the morning session after Piper Sandler analysts upgraded the stock's rating from Neutral to Buy. The improved outlook... 
Via StockStory

Performance

YTD
-28.15%
-28.15%
1 Month
-22.09%
-22.09%
3 Month
-33.15%
-33.15%
6 Month
-63.09%
-63.09%
1 Year
-55.03%
-55.03%

More News

Read More
This HubSpot Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday
Via Benzinga
Winners And Losers Of Q4: Myriad Genetics (NASDAQ:MYGN) Vs The Rest Of The Therapeutics Stocks
Via StockStory
Topics Artificial Intelligence
Exposures Artificial Intelligence
Analyst Expectations For Myriad Genetics's Future
Via Benzinga
Expert Outlook: Myriad Genetics Through The Eyes Of 8 Analysts
Via Benzinga
Spotting Winners: Sarepta Therapeutics (NASDAQ:SRPT) And Therapeutics Stocks In Q4
Via StockStory
Topics Artificial Intelligence
Exposures Artificial Intelligence
Myriad Genetics Faces Cost Restructuring As UnitedHealthcare Ends GeneSight Coverage, Appoints New CEO
Via Benzinga
Why Myriad Genetics (MYGN) Shares Are Plunging Today
Via StockStory
Sarepta Therapeutics (SRPT) To Report Earnings Tomorrow: Here Is What To Expect
Via StockStory
Myriad Genetics and Gabbi to Work Together to Increase Access to Hereditary Cancer Risk Assessment Tools
From Myriad Genetics, Inc.
Via GlobeNewswire
What To Expect From United Therapeutics’s (UTHR) Q4 Earnings
Via StockStory
Myriad Genetics (NASDAQ:MYGN) Misses Q4 Sales Targets, Stock Drops
Via StockStory
Myriad Genetics Reports Fourth Quarter and Full-Year 2024 Financial Results; Full-year 2024 revenue of $838 million grew 11% year-over-year, the second consecutive year of double-digit revenue growth
From Myriad Genetics, Inc.
Via GlobeNewswire
Myriad Genetics Announces Senior Leadership Transition
From Myriad Genetics, Inc.
Via GlobeNewswire
Myriad Genetics Partners with PATHOMIQ to add Artificial Intelligence Technology Platform to its Oncology Portfolio
From Myriad Genetics, Inc.
Via GlobeNewswire
Earnings Scheduled For February 24, 2025
Via Benzinga
What To Expect From Myriad Genetics’s (MYGN) Q4 Earnings
Via StockStory
Myriad Genetics Included in Forbes America’s Best Employers 2025 List
From Myriad Genetics, Inc.
Via GlobeNewswire
Myriad Genetics to Release Fourth Quarter and Full Year 2024 Financial Results on February 24, 2025
From Myriad Genetics, Inc.
Via GlobeNewswire
3 Reasons to Sell MYGN and 1 Stock to Buy Instead
Via StockStory
Myriad Genetics and CancerCARE for Life Announce Agreement to Advance Access to MyRisk with RiskScore Hereditary Cancer Test
From Myriad Genetics, Inc.
Via GlobeNewswire
Myriad Genetics Announces Two New Patents Granted for its Molecular Residual Disease (MRD) Assay
From Myriad Genetics, Inc.
Via GlobeNewswire
Myriad Genetics and Lumea Collaborate to Enhance Access to the Prolaris Biomarker and MyRisk Hereditary Cancer Tests through BxLink Integration
From Myriad Genetics, Inc.
Via GlobeNewswire
Myriad Genetics Unveils Groundbreaking Eight Weeks’ Gestation NIPT Study Results at Society for Maternal-Fetal Medicine Conference
From Myriad Genetics, Inc.
Via GlobeNewswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.